{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:15:49Z","timestamp":1789038949467,"version":"build-2803163510"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40265-026-02304-2","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:54:51Z","timestamp":1774436091000},"page":"719-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Anti-nerve Growth Factor Monoclonal Antibodies in Managing Chronic Musculoskeletal Pain: A Systematic Review with Network Meta-analysis"],"prefix":"10.1007","volume":"86","author":[{"given":"Ahmed","family":"Abouelella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qasi","family":"Najah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard O.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Arendt-Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Lopez-Olivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew K.","family":"Bagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. T. Matthew","family":"Seah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alhasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hamoudah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Abuzied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Al-tamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Basheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham","family":"Mahgoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6406-4212","authenticated-orcid":false,"given":"Muhammed","family":"Elhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"8","key":"2304_CR1","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40520-019-01163-0","volume":"31","author":"MA Clynes","year":"2019","unstructured":"Clynes MA, Jameson KA, Edwards MH, Cooper C, Dennison EM. Impact of osteoarthritis on activities of daily living: does joint site matter? Aging Clin Exp Res. 2019;31(8):1049\u201356.","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"2304_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/21642850.2021.2022487","volume":"10","author":"A Agnus Tom","year":"2022","unstructured":"Agnus Tom A, Rajkumar E, John R, Joshua George A. Determinants of quality of life in individuals with chronic low back pain: a systematic review. Health Psychol Behav Med. 2022;10(1):124\u201344.","journal-title":"Health Psychol Behav Med"},{"key":"2304_CR3","unstructured":"Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(9):e508-e22."},{"issue":"10182","key":"2304_CR4","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","volume":"393","author":"DJ Hunter","year":"2019","unstructured":"Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745\u201359.","journal-title":"Lancet"},{"issue":"5","key":"2304_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/rheumatology\/ket463","volume":"53","author":"SR Kingsbury","year":"2014","unstructured":"Kingsbury SR, Gross HJ, Isherwood G, Conaghan PG. Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries. Rheumatology (Oxford). 2014;53(5):937\u201347.","journal-title":"Rheumatology (Oxford)"},{"issue":"10440","key":"2304_CR6","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"AJ Ferrari","year":"2024","unstructured":"Ferrari AJ, Santomauro DF, Aali A, Abate YH, Abbafati C, Abbastabar H, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2024;403(10440):2133\u201361.","journal-title":"The Lancet"},{"issue":"9859","key":"2304_CR7","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","volume":"380","author":"T Vos","year":"2012","unstructured":"Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163\u201396.","journal-title":"Lancet"},{"issue":"6","key":"2304_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/MOG.0b013e32833e91eb","volume":"26","author":"SC Ng","year":"2010","unstructured":"Ng SC, Chan FK. NSAID-induced gastrointestinal and cardiovascular injury. Curr Opin Gastroenterol. 2010;26(6):611\u20137.","journal-title":"Curr Opin Gastroenterol"},{"issue":"7","key":"2304_CR9","doi-asserted-by":"publisher","first-page":"480","DOI":"10.7326\/M16-2458","volume":"166","author":"R Chou","year":"2017","unstructured":"Chou R, Deyo R, Friedly J, Skelly A, Weimer M, Fu R, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(7):480\u201392.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2304_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/acr.23884","volume":"72","author":"MC Osani","year":"2020","unstructured":"Osani MC, Vaysbrot EE, Zhou M, McAlindon TE, Bannuru RR. Duration of symptom relief and early trajectory of adverse events for oral nonsteroidal antiinflammatory drugs in knee osteoarthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2020;72(5):641\u201351.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"15","key":"2304_CR11","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","volume":"315","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016. JAMA. 2016;315(15):1624\u201345.","journal-title":"JAMA"},{"issue":"4819","key":"2304_CR12","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1126\/science.3306916","volume":"237","author":"R Levi-Montalcini","year":"1987","unstructured":"Levi-Montalcini R. The nerve growth factor 35 years later. Science. 1987;237(4819):1154\u201362.","journal-title":"Science"},{"issue":"6","key":"2304_CR13","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1023\/A:1022475432077","volume":"23","author":"DA Halliday","year":"1998","unstructured":"Halliday DA, Zettler C, Rush RA, Scicchitano R, McNeil JD. Elevated nerve growth factor levels in the synovial fluid of patients with inflammatory joint disease. Neurochem Res. 1998;23(6):919\u201322.","journal-title":"Neurochem Res"},{"issue":"1","key":"2304_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1124\/mi.7.1.6","volume":"7","author":"GD Nicol","year":"2007","unstructured":"Nicol GD, Vasko MR. Unraveling the story of NGF-mediated sensitization of nociceptive sensory neurons: on or off the Trks? Mol Interv. 2007;7(1):26\u201341.","journal-title":"Mol Interv"},{"issue":"2","key":"2304_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0306-4522(94)90366-2","volume":"62","author":"CJ Woolf","year":"1994","unstructured":"Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience. 1994;62(2):327\u201331.","journal-title":"Neuroscience"},{"key":"2304_CR16","doi-asserted-by":"crossref","unstructured":"Svensson P, Cairns BE, Wang K, Arendt-Nielsen L. Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. PAIN. 2003;104(1).","DOI":"10.1016\/S0304-3959(03)00012-5"},{"issue":"3","key":"2304_CR17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00221-008-1531-5","volume":"191","author":"H Andersen","year":"2008","unstructured":"Andersen H, Arendt-Nielsen L, Svensson P, Danneskiold-Sams\u00f8e B, Graven-Nielsen T. Spatial and temporal aspects of muscle hyperalgesia induced by nerve growth factor in humans. Exp Brain Res. 2008;191(3):371\u201382.","journal-title":"Exp Brain Res"},{"issue":"6","key":"2304_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/0063030-200822060-00002","volume":"22","author":"JJ Watson","year":"2008","unstructured":"Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs. 2008;22(6):349\u201359.","journal-title":"BioDrugs"},{"issue":"1","key":"2304_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/1479-5876-10-239","volume":"10","author":"L Aloe","year":"2012","unstructured":"Aloe L, Rocco ML, Bianchi P, Manni L. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med. 2012;10(1):239.","journal-title":"J Transl Med"},{"issue":"11","key":"2304_CR20","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.joca.2019.05.028","volume":"27","author":"E Krupka","year":"2019","unstructured":"Krupka E, Jiang GL, Jan C. Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study. Osteoarthr Cartil. 2019;27(11):1599\u2013607.","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"2304_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/bcp.13448","volume":"84","author":"P Loudon","year":"2018","unstructured":"Loudon P, Siebenga P, Gorman D, Gore K, Dua P, van Amerongen G, et al. Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models. Br J Clin Pharmacol. 2018;84(2):301\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2304_CR22","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.joca.2019.05.029","volume":"27","author":"FE Watt","year":"2019","unstructured":"Watt FE, Blauwet MB, Fakhoury A, Jacobs H, Smulders R, Lane NE. Tropomyosin-related kinase a (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial. Osteoarthritis Cartilage. 2019;27(11):1590\u20138.","journal-title":"Osteoarthritis Cartilage"},{"issue":"8","key":"2304_CR23","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1110\/ps.035402.108","volume":"17","author":"YN Abdiche","year":"2008","unstructured":"Abdiche YN, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci. 2008;17(8):1326\u201335.","journal-title":"Protein Sci"},{"issue":"3","key":"2304_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1517\/14728214.2011.576670","volume":"16","author":"GL Matthews","year":"2011","unstructured":"Matthews GL, Hunter DJ. Emerging drugs for osteoarthritis. Expert Opin Emerg Drugs. 2011;16(3):479\u201391.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"4","key":"2304_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/annrheumdis-2020-217259","volume":"80","author":"P Dakin","year":"2021","unstructured":"Dakin P, Kivitz AJ, Gimbel JS, Skrepnik N, DiMartino SJ, Emeremni CA, et al. Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II\/III randomised clinical trial. Ann Rheum Dis. 2021;80(4):509\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2304_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12891-025-08402-8","volume":"26","author":"SJ DiMartino","year":"2025","unstructured":"DiMartino SJ, Gao H, Eng S, Valenzuela G, Fuerst T, Emeremni C, et al. Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip. BMC Musculoskelet Disord. 2025;26(1):192.","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"2304_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/ijcp.12807","volume":"70","author":"AJ Mayorga","year":"2016","unstructured":"Mayorga AJ, Wang S, Kelly KM, Thipphawong J. Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial. Int J Clin Pract. 2016;70(6):493\u2013505.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"2304_CR28","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/annrheumdis-2019-216296","volume":"79","author":"F Berenbaum","year":"2020","unstructured":"Berenbaum F, Blanco FJ, Guermazi A, Miki K, Yamabe T, Viktrup L, et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann Rheum Dis. 2020;79(6):800\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2304_CR29","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1002\/art.41674","volume":"73","author":"MC Hochberg","year":"2021","unstructured":"Hochberg MC, Carrino JA, Schnitzer TJ, Guermazi A, Walsh DA, White A, et al. Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial. Arthritis Rheumatol. 2021;73(7):1167\u201377.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2304_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2217\/pmt-2021-0040","volume":"12","author":"S-i Konno","year":"2022","unstructured":"Konno S-i, Nikaido T, Markman JD, Ohta M, Machida T, Isogawa N, et al. Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled\u00a0Japanese\u00a0phase III\u00a0safety study. Pain Manag. 2022;12(3):323\u201335.","journal-title":"Pain Manag"},{"issue":"10","key":"2304_CR31","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.pain.2013.05.051","volume":"154","author":"P Sanga","year":"2013","unstructured":"Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J, et al. Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. Pain. 2013;154(10):1910\u20139.","journal-title":"Pain"},{"issue":"1","key":"2304_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2019.8044","volume":"322","author":"TJ Schnitzer","year":"2019","unstructured":"Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA. 2019;322(1):37\u201348.","journal-title":"JAMA"},{"issue":"7","key":"2304_CR33","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.pain.2014.03.018","volume":"155","author":"PJ Tiseo","year":"2014","unstructured":"Tiseo PJ, Kivitz AJ, Ervin JE, Ren H, Mellis SJ. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. Pain. 2014;155(7):1245\u201352.","journal-title":"Pain"},{"issue":"9","key":"2304_CR34","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1097\/j.pain.0000000000001928","volume":"161","author":"JD Markman","year":"2020","unstructured":"Markman JD, Bolash RB, McAlindon TE, Kivitz AJ, Pombo-Suarez M, Ohtori S, et al. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety. Pain. 2020;161(9):2068\u201378.","journal-title":"Pain"},{"key":"2304_CR35","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.joca.2014.10.005","volume":"23","author":"MC Hochberg","year":"2015","unstructured":"Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage. 2015;23:S18\u201321.","journal-title":"Osteoarthritis Cartilage"},{"key":"2304_CR36","unstructured":"Adams B. Regeneron and Teva\u2019s fasinumab hit with FDA clinical hold2016. Available from: https:\/\/www.fiercebiotech.com\/biotech\/regeneron-and-teva-s-fasinumab-hit-fda-clinical-hold."},{"issue":"13","key":"2304_CR37","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s40265-017-0781-6","volume":"77","author":"B Bannwarth","year":"2017","unstructured":"Bannwarth B, Kostine M. Nerve growth factor antagonists: is the future of monoclonal antibodies becoming clearer? Drugs. 2017;77(13):1377\u201387.","journal-title":"Drugs"},{"key":"2304_CR38","unstructured":"McKenzie H. Eli Lilly and Pfizer Put Osteoarthritis Pain Drug Tanezumab Out of its Misery2021. Available from: https:\/\/www.biospace.com\/eli-lilly-and-pfizer-put-once-promising-osteoarthritis-pain-drug-out-of-its-misery."},{"key":"2304_CR39","unstructured":"Portal TA. Not approved in the EU: Another setback for the drug tanezumab. Lund University2021 [updated 05\/2022. Available from: https:\/\/www.arthritisportal.lu.se\/article\/not-approved-eu-another-setback-drug-tanezumab."},{"key":"2304_CR40","unstructured":"Taylor P. And then there were none: Regeneron cans last late-stage NGF drug. Pharmaphorum2022 [updated 11\/2022. Available from: https:\/\/pharmaphorum.com\/news\/and-then-there-were-none-regeneron-cans-last-late-stage-ngf-drug."},{"issue":"6","key":"2304_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157105","volume":"11","author":"SL Kan","year":"2016","unstructured":"Kan SL, Li Y, Ning GZ, Yuan ZF, Chen LX, Bi MC, et al. Tanezumab for patients with osteoarthritis of the knee: a meta-analysis. PLoS ONE. 2016;11(6):e0157105.","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"2304_CR42","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.joca.2014.10.003","volume":"23","author":"TJ Schnitzer","year":"2015","unstructured":"Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis Cartilage. 2015;23(Suppl 1):S8-17.","journal-title":"Osteoarthritis Cartilage"},{"issue":"2","key":"2304_CR43","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/pm\/pnw262","volume":"18","author":"J Chen","year":"2017","unstructured":"Chen J, Li J, Li R, Wang H, Yang J, Xu J, et al. Efficacy and safety of tanezumab on osteoarthritis knee and hip pains: a meta-analysis of randomized controlled trials. Pain Med. 2017;18(2):374\u201385.","journal-title":"Pain Med"},{"issue":"6","key":"2304_CR44","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s10067-020-05488-4","volume":"40","author":"ZR Fan","year":"2021","unstructured":"Fan ZR, Ma JX, Wang Y, Chen HT, Lang S, Ma XL. Efficacy and safety of Tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled Phase III trials. Clin Rheumatol. 2021;40(6):2155\u201365.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"2304_CR45","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/pm\/pnaa260","volume":"22","author":"Y Yu","year":"2021","unstructured":"Yu Y, Lu ST, Sun JP, Zhou W. Safety of low-dose Tanezumab in the treatment of hip or knee osteoarthritis: a systemic review and meta-analysis of randomized Phase III clinical trials. Pain Med. 2021;22(3):585\u201395.","journal-title":"Pain Med"},{"issue":"2","key":"2304_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5414\/CP203812","volume":"59","author":"GG Song","year":"2021","unstructured":"Song GG, Lee YH. Relative efficacy and tolerability of 2.5, 5, and 10 mg tanezumab for the treatment of osteoarthritis: a Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. Int J Clin Pharmacol Ther. 2021;59(2):147\u201355.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"2304_CR47","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1097\/AJP.0000000000000986","volume":"37","author":"B Zhang","year":"2021","unstructured":"Zhang B, Tian X, Qu Z, Liu J, Yang L. Relative efficacy and safety of Tanezumab for osteoarthritis: a systematic review and meta-analysis of randomized-controlled trials. Clin J Pain. 2021;37(12):914\u201324.","journal-title":"Clin J Pain"},{"issue":"12","key":"2304_CR48","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.clinthera.2021.10.011","volume":"43","author":"Y-z Cai","year":"2021","unstructured":"Cai Y-z, Nie L-y, Ruan J-q, Zhao K. Effectiveness of various dosages and administration methods of tanezumab for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Clin Therap. 2021;43(12):2116\u201326.","journal-title":"Clin Therap"},{"issue":"7","key":"2304_CR49","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1530\/EOR-21-0103","volume":"7","author":"D Zhao","year":"2022","unstructured":"Zhao D, Zeng L-f, Liang G-h, Pan J-k, Luo M-h, Han Y-h, et al. Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials. EFORT Open Rev. 2022;7(7):470\u201380.","journal-title":"EFORT Open Rev"},{"issue":"1","key":"2304_CR50","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/WNF.0000000000000530","volume":"46","author":"J Lian","year":"2023","unstructured":"Lian J, Wang J, Li X, Yang S, Li H, Zhong Y, et al. Different dosage regimens of tanezumab for the treatment of chronic low back pain: a meta-analysis of randomized controlled trials. Clin Neuropharmacol. 2023;46(1):6\u201316.","journal-title":"Clin Neuropharmacol"},{"key":"2304_CR51","first-page":"2020","volume":"11","author":"S Yang","year":"2020","unstructured":"Yang S, Huang Y, Ye Z, Li L, Zhang Y. The Efficacy of nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: a meta-analysis. Front Pharmacol. 2020;11:2020.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2304_CR52","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/pm\/pnaa441","volume":"22","author":"KTM Seah","year":"2021","unstructured":"Seah KTM, Rammanohar J, Sutton J, To K, Khan WS. The effectiveness of anti-nerve growth factor monoclonal antibodies in the management of pain in osteoarthritis of the hip and knee: a PRISMA systematic review and meta-analysis. Pain Med. 2021;22(5):1185\u2013204.","journal-title":"Pain Med"},{"key":"2304_CR53","doi-asserted-by":"crossref","unstructured":"The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777\u201384.","DOI":"10.7326\/M14-2385"},{"issue":"2","key":"2304_CR54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","volume":"17","author":"JP Jansen","year":"2014","unstructured":"Jansen JP, Trikalinos T, Cappelleri JC, Daw J, Andes S, Eldessouki R, et al. Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force Report. Value in Health. 2014;17(2):157\u201373.","journal-title":"Value in Health."},{"key":"2304_CR55","doi-asserted-by":"crossref","unstructured":"Scientific approach to the assessment and management of activity-related spinal disorders. A monograph for clinicians. Report of the Quebec Task Force on Spinal Disorders. Spine (Phila Pa 1976). 1987;12(7 Suppl):S1-59.","DOI":"10.1097\/00007632-198709001-00001"},{"issue":"12","key":"2304_CR56","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1080\/03007995.2019.1653068","volume":"35","author":"KM Kelly","year":"2019","unstructured":"Kelly KM, Sanga P, Zaki N, Wang S, Haeussler J, Louie J, et al. Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies. Curr Med Res Opin. 2019;35(12):2117\u201327.","journal-title":"Curr Med Res Opin"},{"key":"2304_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.05.003","author":"N Katz","year":"2011","unstructured":"Katz N, Borenstein DG, Birbara C, Bramson C, Nemeth MA, Smith MD, et al. Efficacy and safety of Tanezumab in the treatment of chronic low back pain. Pain. 2011. https:\/\/doi.org\/10.1016\/j.pain.2011.05.003.","journal-title":"Pain"},{"issue":"1","key":"2304_CR58","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44770","volume":"5","author":"T Olivier","year":"2022","unstructured":"Olivier T, Haslam A, Prasad V. Reporting of physicians\u2019 or investigators\u2019 choice of treatment in oncology randomized clinical trials. JAMA Netw Open. 2022;5(1):e2144770.","journal-title":"JAMA Netw Open"},{"key":"2304_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"2304_CR60","unstructured":"Higgins JPT LT, Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect In: Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor. Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024.August 2023."},{"issue":"1","key":"2304_CR61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2288-13-35","volume":"13","author":"U Krahn","year":"2013","unstructured":"Krahn U, Binder H, K\u00f6nig J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol. 2013;13(1):35.","journal-title":"BMC Med Res Methodol"},{"key":"2304_CR62","unstructured":"Sch\u00fcnemann H BJ, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations.: The GRADE Working Group; 2013 [updated October 2013. Available from: guidelinedevelopment.org\/handbook."},{"issue":"7","key":"2304_CR63","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1002\/ejp.1764","volume":"25","author":"F Berenbaum","year":"2021","unstructured":"Berenbaum F, Langford R, Perrot S, Miki K, Blanco FJ, Yamabe T, et al. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained? Eur J Pain. 2021;25(7):1525\u201339.","journal-title":"Eur J Pain"},{"key":"2304_CR64","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/JPR.S135257","volume":"11","author":"C Birbara","year":"2018","unstructured":"Birbara C, Dabezies EJ Jr, Burr AM, Fountaine RJ, Smith MD, Brown MT, et al. Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis. J Pain Res. 2018;11:151\u201364.","journal-title":"J Pain Res"},{"issue":"1","key":"2304_CR65","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jns.2014.07.028","volume":"345","author":"MT Brown","year":"2014","unstructured":"Brown MT, Herrmann DN, Goldstein M, Burr AM, Smith MD, West CR, et al. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J Neurol Sci. 2014;345(1):139\u201347.","journal-title":"J Neurol Sci"},{"issue":"8","key":"2304_CR66","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jpain.2012.05.006","volume":"13","author":"MT Brown","year":"2012","unstructured":"Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain. 2012;13(8):790\u20138.","journal-title":"J Pain"},{"issue":"7","key":"2304_CR67","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/art.37950","volume":"65","author":"MT Brown","year":"2013","unstructured":"Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum. 2013;65(7):1795\u2013803.","journal-title":"Arthritis Rheum"},{"key":"2304_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120184","author":"MT Brown","year":"2022","unstructured":"Brown MT, Sandroni P, Low PA, Gorson KC, Hunter DJ, Pixton GC, et al. Neurological safety of subcutaneous Tanezumab versus NSAID in patients with osteoarthritis. J Neurol Sci. 2022. https:\/\/doi.org\/10.1016\/j.jns.2022.120184.","journal-title":"J Neurol Sci"},{"key":"2304_CR69","unstructured":"Corporation MTP. Efficacy and safety of MT-5547 in patients with osteoarthritis accompanied by moderate to severe pain. ClinicalTrials.gov ID NCT03245008 ClinicalTrials.gov2023 [updated 2023-05-17. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03245008?cond=NCT03245008&rank=1."},{"issue":"11","key":"2304_CR70","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/art.41012","volume":"71","author":"P Dakin","year":"2019","unstructured":"Dakin P, DiMartino SJ, Gao H, Maloney J, Kivitz AJ, Schnitzer TJ, et al. The efficacy, tolerability, and joint safety of Fasinumab in osteoarthritis pain: a phase IIb\/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. 2019;71(11):1824\u201334.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"2304_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocarto.2024.100533","volume":"6","author":"SJ DiMartino","year":"2024","unstructured":"DiMartino SJ, Mei J, Schnitzer TJ, Gao H, Eng S, Winslow C, et al. A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip. Osteoarthr Cartil Open. 2024;6(4):100533.","journal-title":"Osteoarthr Cartil Open."},{"issue":"11","key":"2304_CR72","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3899\/jrheum.131294","volume":"41","author":"EF Ekman","year":"2014","unstructured":"Ekman EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, et al. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol. 2014;41(11):2249\u201359.","journal-title":"J Rheumatol"},{"issue":"7","key":"2304_CR73","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.pain.2013.03.006","volume":"154","author":"AJ Kivitz","year":"2013","unstructured":"Kivitz AJ, Gimbel JS, Bramson C, Nemeth MA, Keller DS, Brown MT, et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain. 2013;154(7):1009\u201321.","journal-title":"Pain"},{"issue":"16","key":"2304_CR74","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa0901510","volume":"363","author":"NE Lane","year":"2010","unstructured":"Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363(16):1521\u201331.","journal-title":"N Engl J Med"},{"issue":"4","key":"2304_CR75","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s40122-022-00424-7","volume":"11","author":"JD Markman","year":"2022","unstructured":"Markman JD, Schnitzer TJ, Perrot S, Beydoun SR, Ohtori S, Viktrup L, et al. Clinical meaningfulness of response to tanezumab in patients with chronic low back pain: analysis from a 56-week, randomized, placebo- and tramadol-controlled, phase 3 trial. Pain Ther. 2022;11(4):1267\u201385.","journal-title":"Pain Ther"},{"issue":"12","key":"2304_CR76","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.joca.2011.09.006","volume":"19","author":"H Nagashima","year":"2011","unstructured":"Nagashima H, Suzuki M, Araki S, Yamabe T, Muto C. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage. 2011;19(12):1405\u201312.","journal-title":"Osteoarthritis Cartilage"},{"key":"2304_CR77","unstructured":"Pharmaceuticals R. A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA1). ClinicalTrials.gov ID NCT03161093 ClinicalTrials.gov2022 [updated 2022-11-14. Available from: https:\/\/clinicaltrials.gov.\/study\/NCT03161093?term=NCT03161093&rank=."},{"key":"2304_CR78","unstructured":"Pharmaceuticals R. Study to EVALUATE the effects of fasinumab on peripheral nerve function in patients with pain due to osteoarthritis of the hip or knee. ClinicalTrials.gov ID NCT03691974 ClinicalTrials.gov2023 [updated 2023-03-01. Available from: https:\/\/clinicaltrials.gov.\/study\/NCT03691974?cond=NCT03691974&rank=1."},{"issue":"4","key":"2304_CR79","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/art.39943","volume":"69","author":"P Sanga","year":"2017","unstructured":"Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J, et al. Long-term safety and efficacy of fulranumab in patients with moderate-to-severe osteoarthritis pain: a phase II randomized, double-blind, placebo-controlled extension study. Arthritis Rheumatol. 2017;69(4):763\u201373.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2304_CR80","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.clinthera.2016.03.030","volume":"38","author":"P Sanga","year":"2016","unstructured":"Sanga P, Polverejan E, Wang S, Kelly KM, Thipphawong J. Efficacy, safety, and tolerability of Fulranumab as an adjunctive therapy in patients with inadequately controlled, moderate-to-severe chronic low back pain: a randomized, double-blind, placebo-controlled, dose-ranging, dose-loading phase II study. Clin Ther. 2016;38(6):1435\u201350.","journal-title":"Clin Ther"},{"issue":"6","key":"2304_CR81","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/annrheumdis-2013-204905","volume":"74","author":"TJ Schnitzer","year":"2015","unstructured":"Schnitzer TJ, Ekman EF, Spierings EL, Greenberg HS, Smith MD, Brown MT, et al. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis. 2015;74(6):1202\u201311.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2304_CR82","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.pain.2013.04.035","volume":"154","author":"ELH Spierings","year":"2013","unstructured":"Spierings ELH, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 2013;154(9):1603\u201312.","journal-title":"Pain"},{"issue":"3","key":"2304_CR83","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000653","volume":"3","author":"PA Walicke","year":"2018","unstructured":"Walicke PA, Hefti F, Bales R, Lu S-P, Ruckle JL, Brown MT, et al. First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain. PAIN Reports. 2018;3(3):e653.","journal-title":"PAIN Reports."},{"issue":"1","key":"2304_CR84","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.18632\/aging.202232","volume":"13","author":"Z Cao","year":"2020","unstructured":"Cao Z, Zhou J, Long Z, Li Y, Sun J, Luo Y, et al. Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs. Aging (Albany NY). 2020;13(1):1051\u201370.","journal-title":"Aging (Albany NY)."},{"issue":"4","key":"2304_CR85","doi-asserted-by":"publisher","DOI":"10.1177\/23259671221088590","volume":"10","author":"Y Gao","year":"2022","unstructured":"Gao Y, Hu Z, Huang Y, Liu W, Ren C. Efficacy and safety of Anti\u2013Nerve Growth Factor antibody therapy for hip and knee osteoarthritis: A meta-analysis. Orthop J Sports Med. 2022;10(4):23259671221088590.","journal-title":"Orthop J Sports Med"},{"key":"2304_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.727771","volume":"12","author":"Z Cao","year":"2021","unstructured":"Cao Z, Li Q, Guo J, Li Y, Wu J. Is targeting Nerve Growth Factor Antagonist a new option for pharmacologic treatment of low back pain? A supplemental network meta-analysis of the American College of Physicians guidelines. Front Pharmacol. 2021;12:727771.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2304_CR87","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/art.39493","volume":"68","author":"AJ Teichtahl","year":"2016","unstructured":"Teichtahl AJ, Cicuttini FM. Editorial: Pain relief in osteoarthritis: The potential for a perfect storm. Arthritis Rheumatol. 2016;68(2):270\u20133.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2304_CR88","doi-asserted-by":"publisher","first-page":"R16","DOI":"10.1186\/ar4443","volume":"16","author":"E Pecchi","year":"2014","unstructured":"Pecchi E, Priam S, Gosset M, Pigenet A, Sudre L, Laiguillon M-C, et al. Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain. Arthritis Res Ther. 2014;16(1):R16.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"2304_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222602","volume":"14","author":"CJM Stapledon","year":"2019","unstructured":"Stapledon CJM, Tsangari H, Solomon LB, Campbell DG, Hurtado P, Krishnan R, et al. Human osteocyte expression of Nerve Growth Factor: The effect of Pentosan Polysulphate Sodium (PPS) and implications for pain associated with knee osteoarthritis. PLoS ONE. 2019;14(9):e0222602.","journal-title":"PLoS ONE"},{"issue":"3","key":"2304_CR90","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/0363546505280428","volume":"34","author":"DB Cohen","year":"2006","unstructured":"Cohen DB, Kawamura S, Ehteshami JR, Rodeo SA. Indomethacin and Celecoxib impair rotator cuff tendon-to-bone healing. Am J Sports Med. 2006;34(3):362\u20139.","journal-title":"Am J Sports Med"},{"issue":"8","key":"2304_CR91","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1177\/0091270003256061","volume":"43","author":"AT Harder","year":"2003","unstructured":"Harder AT, An YH. The mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: a concise review. J Clin Pharmacol. 2003;43(8):807\u201315.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"2304_CR92","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1136\/annrheumdis-2012-203164","volume":"73","author":"AR Balanescu","year":"2014","unstructured":"Balanescu AR, Feist E, Wolfram G, Davignon I, Smith MD, Brown MT, et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis. 2014;73(9):1665\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2304_CR93","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.joca.2023.10.008","volume":"32","author":"AE Nelson","year":"2024","unstructured":"Nelson AE. Multiple joint osteoarthritis (MJOA): what\u2019s in a name? Osteoarthritis Cartilage. 2024;32(3):234\u201340.","journal-title":"Osteoarthritis Cartilage"},{"key":"2304_CR94","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s13075-015-0797-9","volume":"17","author":"JM Gow","year":"2015","unstructured":"Gow JM, Tsuji WH, Williams GJ, Mytych D, Sciberras D, Searle SL, et al. Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects. Arthritis Res Ther. 2015;17:282.","journal-title":"Arthritis Res Ther"},{"key":"2304_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2024.1395360","volume":"11","author":"J Reid","year":"2024","unstructured":"Reid J, Gildea E, Davies V, Thompson J, Scott M. Measuring the effect of the anti-nerve growth factor antibodies Bedinvetmab and Frunevetmab on quality of life in dogs and cats with osteoarthritis using a validated health-related quality of life outcome measure: an observational real-world study. Front Vet Sci. 2024;11:1395360.","journal-title":"Front Vet Sci"},{"key":"2304_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2024.111537","volume":"176","author":"ID Florez","year":"2024","unstructured":"Florez ID, De La Cruz-Mena JE, Veroniki A-A. Network meta-analysis: a powerful tool for clinicians, decision-makers, and methodologists. J Clin Epidemiol. 2024;176:111537.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2304_CR97","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","volume":"6","author":"L Mbuagbaw","year":"2017","unstructured":"Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017;6(1):79.","journal-title":"Syst Rev"},{"issue":"5","key":"2304_CR98","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/jrsm.1700","volume":"15","author":"AE Ades","year":"2024","unstructured":"Ades AE, Welton NJ, Dias S, Phillippo DM, Caldwell DM. Twenty years of network meta-analysis: continuing controversies and recent developments. Res Synth Methods. 2024;15(5):702\u201327.","journal-title":"Res Synth Methods"},{"issue":"1","key":"2304_CR99","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/sim.5512","volume":"32","author":"CD Giovane","year":"2013","unstructured":"Giovane CD, Vacchi L, Mavridis D, Filippini G, Salanti G. Network meta-analysis models to account for variability in treatment definitions: application to dose effects. Stat Med. 2013;32(1):25\u201339.","journal-title":"Stat Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02304-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02304-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02304-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:02:38Z","timestamp":1777006958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02304-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2304"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02304-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors (A.A, Q.N, R.D, L.A.N, M.L.O, M.K.B, K.T.M.S, M.A, A.H, O.A, M.A, A.I, E.B, R.M, M.E) declare that there is no conflict of interest in this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As this review was based exclusively on published literature, a statement of ethics is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of Ethics"}},{"value":"This review was based on previously published peer-reviewed articles and publicly available clinical trials, from which the data used in this analysis were extracted; no new data were generated. A full list of the included studies and patient characteristics is available in the supplementary materials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (participation & publication)"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability:"}},{"value":"Conception and design: Ahmed Abouelella, Qasi Najah, Richard O. Day, Lars Arendt-Nielsen, Maria A. Lopez-Olivo, Matthew K. Bagg, K.T. Matthew Seah, Muhammed Elhadi. Collection, assembly of data, and quality assessment: Ahmed Abouelella, Qasi Najah, Mohammad Alhasan, Ahmed Hamoudah, Ola Abuzied, Mansoor Al-tamimi, Ayman Ibrahim, Eman Basheer, Reham Mahgoub. Analysis and interpretation of the data: Ahmed Abouelella, Qasi Najah, Richard O. Day, Lars Arendt-Nielsen, Maria A. Lopez-Olivo, Matthew K. Bagg, K.T. Matthew Seah, Muhammed Elhadi. Drafting of the article: Ahmed Abouelella, Qasi Najah, Richard O. Day, Lars Arendt-Nielsen, Maria A. Lopez-Olivo, Matthew K. Bagg, K.T. Matthew Seah, Muhammed Elhadi. Critical revision of the article for important intellectual content: Richard O. Day, Lars Arendt-Nielsen, Maria A. Lopez-Olivo, Matthew K. Bagg, K.T. Matthew Seah, Mohammad Alhasan, Ahmed Hamoudah, Ola Abuzied, Mansoor Al-tamimi, Ayman Ibrahim, Eman Basheer, Reham Mahgoub, Qasi Najah, Ahmed Abouelella, Muhammed Elhadi. Final approval of the article: All authors have read and approved the final version of the article. Provision of study materials or patients: Not applicable (systematic review and network meta-analysis based exclusively on published data). Statistical expertise: Ahmed Abouelella, Qasi Najah, Muhammed Elhadi. Administrative, technical, or logistic support: Ahmed Hamoudah, Muhammed Elhadi. Supervision: Richard O. Day, Lars Arendt-Nielsen, Muhammed Elhadi. Responsibility for the integrity of the work: The following authors take responsibility for the integrity of the work as a whole, from study inception to the final manuscript: Muhammed Elhadi, MBBCh, MSc (\n                      muhammed-elhadi@korea.ac.kr\n                      ), Ahmed Abouelella, MBBCh (\n                      ahmedz.abouelella@gmail.com\n                      ) Qasi Najah, MBBCh (qasinajah@gmail.com).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}